Neumora Therapeutics | IPO Presentation Deck | 32 slides · page 9 of 32
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.
Pitch deck · context · establish_context · overcrowded density
Slide locked Sign in to view
Slide schematic 8/8
chart 1/1 list 2/2 paragraph 1/1 source-note 1/1 table 1/1 title 2/2
Components 8
timeline bullet bullet paragraph source-note data headline subtitle
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1